Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear
receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral …

Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough
insulin to control blood glucose, and thiazolidinediones (TZDs) are the only current …

Agonists of the peroxisome proliferator activated receptor gamma (PPARγ) are currently
used for treatment of type 2 diabetes due to their insulin sensitizing and glucose metabolism …

As the prevalence of obesity has increased explosively over the last several decades,
associated metabolic disorders, including type 2 diabetes, dyslipidemia, hypertension, and …

Thiazolidinediones (TZDs) are anti-diabetic drugs that act as insulin sensitizers and are
used in the management of type 2 diabetes mellitus. TZDs, which are ligands for the …

The number of patients with type 2 diabetes mellitus (T2DM), which is mainly characterized
by insulin resistance and insulin secretion deficiency, has been soaring in recent years …

Peroxisome proliferator-activated receptor γ (PPARγ) is a clinically validated target for
treatment of insulin resistance. PPARγ activation by full agonists such as thiazolidinediones …

An epidemic of metabolic diseases including type 2 diabetes and obesity is undermining the
health of people living in industrialized societies. There is an urgent need to develop …

The thiazolidinediones (TZDs) are ligands of PPARγ that improve insulin sensitivity, but their
use is limited by significant side effects. Recently, we demonstrated a mechanism wherein …

The nuclear receptor PPARγ is a ligand-activated transcription factor that plays an important
role in the control of gene expression linked to a variety of physiological processes. PPARγ …